Menu Search
Equities

Biocytogen Pharmaceuticals Beijing Co Ltd

2315:HKG

Biocytogen Pharmaceuticals Beijing Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.01
  • Today's Change-0.150 / -2.44%
  • Shares traded197.00k
  • 1 Year change-54.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Biocytogen Pharmaceuticals Beijing Co Ltd grew revenues 34.28% from 533.88m to 716.91m while net income improved from a loss of 601.95m to a smaller loss of 382.95m.
Gross margin71.97%
Net profit margin-30.46%
Operating margin-14.72%
Return on assets-9.47%
Return on equity-28.68%
Return on investment-12.44%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Biocytogen Pharmaceuticals Beijing Co Ltd fell by 211.28m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 76.65m for operations while cash used for investing totalled 100.28m.
Cash flow per share-0.2596
Price/Cash flow per share--
Book value per share2.02
Tangible book value per share1.95
More ▼

Balance sheet in CNYView more

Biocytogen Pharmaceuticals Beijing Co Ltd has a Debt to Total Capital ratio of 43.60%, a higher figure than the previous year's 24.92%.
Current ratio1.34
Quick ratio1.33
Total debt/total equity0.7777
Total debt/total capital0.436
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.